Thu, Feb 23, 2017 | updated 08:33 AM IST

Immunotherapy shows positive results in metastatic bladder cancer treatment

Updated: Oct 09, 2016 13:47 IST

WashingtonD.C. [USA], Oct. 9 (ANI): Immunotherapy has shown promising results in the first and

second line treatment of metastatic bladder cancer in two phase trials, a recent research

suggests.

Up to half of the patients with metastatic bladder cancer are not eligible for survival

prolonging first line treatment with cisplatin-based chemotherapy.

Survival in these patients is just nine to ten months with currently available alternative

chemotherapy.

The phase II KEYNOTE-052 trial1 evaluated the efficacy and safety of PD-1 blockade with

pembrolizumab as first line therapy in cisplatin ineligible patients with metastatic or locally

advanced bladder cancer.

The researchers presented the preliminary analysis of the first 100 patients enrolled in the

trial.

The primary endpoint of objective response rate was 24 percent.

The biomarker cut point to identify the patients, who are most likely to respond to the drug

was determined to be 10 percent or greater total PD-L1 expression in immune cells or tumor

cells.

Thirty patients had this level of expression of whom 11 (37 percent) responded to treatment.

The median duration of response has not yet been reached and treatment was well tolerated.

Lead author Arjun Balar, said: "Pembrolizumab has substantial activity with a favourable safety

profile as first line therapy in cisplatin ineligible patients with metastatic bladder cancer.

"The biomarker cut point will need to be validated in the larger study population, but seems to

identify patients most likely to respond to pembrolizumab well. Immunotherapy is rapidly

redefining our treatment approach for patients facing this dreadful disease," he added.

For several decades, there had been no global standard of care for second line treatment of

patients with metastatic bladder cancer who progress despite platinum-based chemotherapy until

the recent development of immune checkpoint blockade.

In another study, the phase II CheckMate 275 trial2 assessed the activity and safety of the

PD-1 inhibitor nivolumab in 270 patients with metastatic bladder cancer who have progressed

despite first line platinum-based chemotherapy.

CheckMate 275 is the largest study of a PD-1 inhibitor in bladder cancer reported to date.

In the 265 patients who could be evaluated for efficacy, the primary endpoint of objective

response rate was 19.6 percent.

The median duration of response has not yet been reached, with a median follow-up of seven

months.

In both patients with tumors expressing higher and lower levels of PD-L1 (including those with

less than 1 percent PD-L1), the objective response rate was above that achieved historically

with chemotherapy.

"This data is being submitted to support registration of nivolumab for patients with metastatic

urothelial cancer that has progressed despite platinum-based chemotherapy, an indication for

which the US Food and Drug Administration has granted breakthrough therapy designation to

nivolumab," said lead author Professor Matthew Galsky.

"Immune checkpoint blockade has become the most promising approach for these patients," he

added.

Commenting on the current management of bladder cancer, Maria De Santis, said, "There are

insufficient treatment options for patients ineligible for cisplatin and for those progressing

on cisplatin-based chemotherapy."

"This year the first immune check point inhibitor, atezolizumab, was approved for patients with

bladder cancer and CheckMate 275 provides similar results with nivolumab in the second line

setting," she said.

"KEYNOTE-052 confirms that immunotherapy is also active as first line therapy in cisplatin

ineligible patients, with a slightly lower response rate than chemotherapy. However, the

duration of response with pembrolizumab seems to exceed that of chemotherapy in historical

controls. The protocol included a new biomarker definition and cut-off which needs further

evaluation," said De Santis.

She concluded: "Immune check point inhibitors have started to alter the therapeutic landscape

for bladder cancer. We expect even more dramatic changes in the coming years with the use of

immunotherapy in other clinical stages and as combination therapy."

The study is presented in ESMO 2016. (ANI)

Now, you can cure insomnia with placebo: Study

Updated: Feb 23, 2017 06:27 IST

Washington D.C. [USA], Feb. 23 (ANI): Briton researchers have found a simple placebo may really work well to cure insomnia.

Full Story >>

Washington D.C. [USA], Feb. 23 (ANI): Beware! US researchers warned that taking drugs to reduce gastric acid for prolonged periods may lead to serious kidney problems, including kidney failure.

Full Story >>

New Delhi [India], Feb. 22 (ANI): In rarest of its kind, a paediatric surgery performed by doctors at a city-based hospital gave a new lease of life to a newborn, suffering from a life-threatening defect of the alimentary canal.

Full Story >>

Beware! Zika can be a reason for miscarriage

Updated: Feb 22, 2017 14:18 IST

Washington D.C. (USA), Feb. 22 (ANI): Beware to-be mothers! According to a recent study, Zika virus could lead to a greater risk of miscarriage in the early stage of pregnancy.

Full Story >>

Washington D.C. (USA), Feb. 22 (ANI): Women with a rare type of epithelial ovarian or peritoneum cancer, can now take sigh of relief.

Full Story >>

Washington D.C. [USA], Feb. 22 (ANI): Now don't blame those chips and chocolates for you childs extra pounds, as a study says around 35-40 percent of a child's is inherited from their parents.

Full Story >>

Drinking too much may age arteries over time!

Updated: Feb 22, 2017 06:03 IST

Washington D.C. [USA], Feb. 22 (ANI): Excessive boozing over the years might age arteries prematurely, especially in men, putting them at an increased risk for heart disease.

Full Story >>

Chronic knee pain may be treated online

Updated: Feb 21, 2017 06:41 IST

Washington D.C. [USA], Feb. 21 (ANI): A study has found out that an online intervention, combining home exercise and pain-coping skills training, provided substantial clinical benefits for patients suffering from chronic knee pain.

Full Story >>

Washington D.C. [USA], Feb. 21 (ANI): Only exercise is not enough to maintain that figure, which is an after effect of much toil and sweat!

Full Story >>

New Delhi [India], Feb. 20 (ANI): With rising life expectancy, increasingly sedentary lifestyles and surge in incidence of obesity, India is also witnessing a resultant rise in orthopedic problems as a natural corollary.

Full Story >>

Children inherit obesity from parents: Study

Updated: Feb 20, 2017 14:54 IST

Washington D.C. (USA), Feb. 20 (ANI): A study reveals that 35-40 percent of a child's 'Body Mass Index' - how fat or thin they are - is inherited from their parents.

Full Story >>

New Delhi [India], Feb 20. (ANI): Good news for all those lazy-headed not-really-a-cleanliness-freak out there! Scientists have found out that the obsession with hygiene could even be turning some beneficial bacteria found in the human gut into "endangered species".

Full Story >>

New Delhi [India], Feb 20. (ANI): In order to persuade someone to quit smoking, it is the 'emotions' that need to be triggered rather than inciting fear in an individual.

Full Story >>

No difference between good or bad diet: Study

Updated: Feb 20, 2017 05:54 IST

New Delhi [India], Feb 20. (ANI): Ever faced a choice between Brown and white bread?

Full Story >>

Washington D.C. [USA], Feb. 19 (ANI): To boost sustainability of livestock production, a study finds that gene editing - one of the newest and most promising tools of biotechnology - enables animal breeders to make beneficial genetic changes, without bringing along unwanted genetic changes.

Full Story >>

People with ADHD may have smaller brain volume

Updated: Feb 19, 2017 07:09 IST

New Delhi [India], Feb 19. (ANI): In a latest study it has been found out that people diagnosed with attention deficit hyperactivity disorder (ADHD) have smaller brain volume than those without the disorder.

Full Story >>

New Delhi [India], Feb 19. (ANI): What if we tell you that scientists can actually slow down the process of ageing. Sounds too good to be true right?

Full Story >>

New Delhi [India], Feb 19. (ANI): Lefty or righty? Well it was decided when you were still in your mum's womb!

Full Story >>

Dads-to be face greater risk of depression

Updated: Feb 19, 2017 06:53 IST

New Delhi [India], Feb 19. (ANI): Expecting a baby is always a joyous experience for both the mother and the father, however a latest study has found out that fathers-to-be can be at risk of depression symptoms if they feel stressed or are in poor health.

Full Story >>

New Delhi [India], Feb 19. (ANI): Do you find it difficult hearing out people at a noisy bar or a restaurant even though you have passed the hearing test with flying colors? Well, you might be secretly deaf!

Full Story >>